Investors

Latest News

Expedeon AG signs commercial agreement with Sona Nanotech

August 6th, 2019

The agreement will address limitations in the development of multiplex point-of-care Lateral Flow Assay diagnostic tests Halifax, Canada, Heidelberg, Germany and Cambridge, UK, 06 August 2019 Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) and Sona Nanotech Inc. (CSE: SONA) (“Sona”), today announced they have entered into a commercial agreement to address limitations in development…

View

Expedeon AG introduces Lightning-Link® Metal Labelling Kits to support single cell analysis

June 24th, 2019

Novel antibody labelling immunoassay technology for multiplex immune profiling addresses one of the fastest growing, billion-dollar life science market sectors Heidelberg, Germany and Cambridge, UK, 24 June 2019 Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) announced today it has introduced Lightning-Link® Metal Labelling Kits for use in multiple immunoassay-based applications to support single cell…

View

Expedeon AG adds CaptSure DIY ELISA to immunoassay technology product range

May 28th, 2019

Heidelberg, Germany and Cambridge, UK, 28 May 2019 – CaptSure™ DIY ELISA will complement Expedeon AG’s product offering, as the Company (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) announced today.

View

Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

November 7th, 2018

Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products Heidelberg, Germany and Cambridge, UK, 07 November 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced a supply and license agreement with United States based Life Sciences company, Quanterix Corporation. The agreement provides Quanterix access to Expedeon’s breadth of…

View

Expedeon AG signs supply agreement with Reszon Diagnostics for proprietary colloidal gold technology

September 27th, 2018

Expedeon’s proprietary colloidal gold to be used for manufacturing of diagnostic lateral flow assays Expedeon’s InnovaCoat® GOLD to be assessed for increasing sensitivity of marketed assays Heidelberg, Germany and Cambridge, UK, 27 September 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has signed a three year supply agreement…

View

Expedeon AG adds five new Alexa Fluor labels to its Lightning-Link antibody labeling kit range

August 14th, 2018

Heidelberg, Germany and Cambridge, UK, 14 August 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced the introduction of five new Alexa Fluor® labels to its range of Lightning-Link® antibody labelling kits. The addition further expands Expedeon’s range of labels, offering customers increased choice and flexibility for common fluorescence detection based applications….

View

SYGNIS introduces 2view unique Western blot detection technology

May 9th, 2018

Heidelberg, Germany and Cambridge, UK, 09 May 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the introduction of 2view™, a unique detection method optimised for Western blotting, under its Expedeon brand name. 2view™ is an innovative double labeled secondary antibody that enables extended detection within the widely used Western blot application….

View

SYGNIS completes acquisition of TGR Biosciences

May 8th, 2018

Heidelberg, Germany and Cambridge, UK, 08 May 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the completion of the acquisition of TGR Biosciences (TGR), the Australian research reagents company. TGR and its highly complementary technologies and products along with its strong customer base will significantly contribute to the overall performance of…

View

SYGNIS announces completion of Sales and Marketing team restructuring to support continued strong revenue growth

March 15th, 2018

Heidelberg, Germany and Cambridge, UK, 15 March 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announced the restructuring of its sales and marketing team to drive continued strong revenue growth. A direct sales and distribution team focused on product sales has been formed while a business development team will focus on partnering…

View

SYGNIS completes integration of acquired companies’ products and services under Expedeon brand name

March 6th, 2018

Heidelberg, Germany and Cambridge, UK, 6 March 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), today announced its subsidiaries Innova Biosciences, Expedeon Holdings, and C.B.S. Scientific have united as Expedeon, effective 1 March 2018. The corporate rebranding follows the latest acquisition of Innova Biosciences by SYGNIS AG in June 2017. SYGNIS AG will…

View

SYGNIS AG extends OEM agreement with leading global research tools provider

February 21st, 2018

Heidelberg, Germany and Cambridge, UK, 21 February 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has signed an extended OEM agreement with one of its key strategic partners, a leading global research tools provider to the life science industry….

View

SYGNIS AG Installs Scalable Production Capability for Lightning-Link Antibody Conjugation Technology

January 16th, 2018

Heidelberg, Germany and Cambridge, UK, 16 January 2018: SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Expedeon, and C.B.S. Scientific Company, today announced it has extended the manufacturing capability for its Lightning-Link® technology, currently marketed under the Expedeon brand, to support scalability and bulk production of antibodies. Lightning-Link is…

View